Core Viewpoint - The article discusses the strategic investment by Zhong Shanshan in Jinbo Biotechnology, a company specializing in recombinant collagen products, highlighting the potential for growth in the medical beauty industry and the collaboration's expected synergies [2][4][6]. Group 1: Investment Details - Jinbo Biotechnology announced a strategic investment from Yangshengtang, with a total transaction amount reaching 3.4 billion yuan [1][4]. - The company plans to issue up to 717.57 million shares, accounting for 6.24% of its pre-issue total share capital, aiming to raise no more than 2 billion yuan, which would be the largest cash capital increase in the history of the Beijing Stock Exchange [4]. - Yang Xia, the founder of Jinbo Biotechnology, transferred 575.33 million shares to Hangzhou Jiushi at a price of 243.84 yuan per share, totaling 1.403 billion yuan [4][7]. Group 2: Company Background - Jinbo Biotechnology, founded by Yang Xia, focuses on recombinant human collagen products and has achieved a market value of 40 billion yuan [2][12]. - The company’s main products include various terminal medical devices and functional skincare products based on type A recombinant human collagen [12][14]. - Jinbo Biotechnology's core product, the injectable recombinant type III human collagen, has been widely adopted, with over 2 million applications across approximately 4,000 medical institutions [12][14]. Group 3: Market Dynamics - The medical beauty industry is characterized by high profitability, with Jinbo Biotechnology reporting a revenue of 1.443 billion yuan in 2024, a year-on-year increase of 84.92%, and a net profit of 732 million yuan, up over 140% [14]. - The gross margin of Jinbo Biotechnology reached 92%, surpassing that of leading companies like Kweichow Moutai [14]. - The article notes that the demand for recombinant collagen is growing, with significant consumer interest reflected in social media discussions and product popularity [17][19]. Group 4: Future Prospects - The collaboration between Jinbo Biotechnology and Yangshengtang is expected to enhance product development, industrial production, and market strategy, aiming to create a large-scale industrial production system [6][12]. - The investment is seen as a strategic move to strengthen Jinbo Biotechnology's position in a competitive market, where it currently faces challenges due to its smaller size and limited financial resources [6][12].

Core Viewpoint - Jinsheng New Materials is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may impact its operations and reputation in the market [2][4]. Company Overview - Jinsheng New Materials specializes in the research, production, and sales of plastic packaging containers for cosmetics, offering over 1,000 product specifications to well-known brands such as Estée Lauder, Oushiman, and Shanghai Jahwa [4]. - The company was officially listed on the Shenzhen Stock Exchange's Growth Enterprise Market on July 10, 2020 [4]. Financial Performance - The company's financial performance has deteriorated significantly since its second year post-listing, transitioning from profit to loss starting in 2022. Although there was a slight increase in net profit in 2024, the company remains in a net loss position [4]. - The cumulative losses over the past three years exceed 69 million yuan [5]. - As of March 31, 2025, the total operating revenue was approximately 744.34 million yuan, reflecting a year-on-year increase of 10.97% [5]. - The total operating costs were approximately 770.59 million yuan, leading to an operating loss of approximately 39.90 million yuan [5]. - The net profit for the same period was approximately -38.36 million yuan, marking a year-on-year decrease of 290.10% [5]. Market Position - As of June 27, 2025, Jinsheng New Materials' stock closed at 16.48 yuan per share, with a total market capitalization of 2.5 billion yuan [5].

[Table_Title] 研究报告 Research Report 27 Jun 2025 Research Report on the Entire 618 Cycle of the Beauty Category on both Taobao/Tmall and Douyin Platforms 中国化妆品 China (A-share) Cosmetics 美妆品类 618 全周期淘系和抖音双平台调研报告 寇媛媛 Yuanyuan Kou 吴颖婕 Mindy Wu yy.kou@htisec.com mindy.yj.wu@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 本次 618 期间，淘系为美妆销售主战场但销售略低于预期，抖音美妆增速高于抖音大盘增速。淘系平台 5.13-6.20 的 GMV 略超 400 亿，同比增长超 10%，不及平台预期目标。总体淘系平台大盘增速同样不及预期，主要由于政策 调整导致爆发力减弱，去年跨店满减活动单日 ...

Core Viewpoint - The recent stock issuance by Jinbo Biological, controlled by Zhong Shanshan, aims to raise up to 2 billion RMB to support its growth and development in the collagen market, while also indicating a strategic partnership with Yangshengtang [1][2][7]. Group 1: Company Actions and Financials - Jinbo Biological plans to issue no more than 717,566 shares, representing 6.24% of its total shares before the issuance, to raise funds for a humanized collagen protein database and working capital [1][2]. - The total investment for the projects is 200 million RMB, with 57.5% allocated to the collagen protein project and 42.5% for working capital [2]. - Jinbo Biological's stock price has surged since its listing, with a maximum increase of over 800% from its issue price, reaching a peak of 452.29 RMB [3][9]. Group 2: Market Performance and Growth - Jinbo Biological has shown impressive financial growth, with revenue increasing from 233 million RMB in 2021 to 1.443 billion RMB in 2024, and net profit rising from 57.39 million RMB to 732 million RMB in the same period [9]. - The gross margin improved from 82.29% to 92.02%, and net margin increased from 24.38% to 50.68% [9]. - The Chinese collagen market reached 28.7 billion RMB in 2021, growing at 40.7%, with a significant increase in the penetration of recombinant collagen [9]. Group 3: Strategic Partnerships and Future Outlook - Yangshengtang, controlled by Zhong Shanshan, is entering into a strategic partnership with Jinbo Biological, which is expected to enhance business synergies and accelerate the implementation of their strategic goals [7][8]. - The collaboration aims to leverage technological integration and market channel empowerment, potentially leading to significant advancements in product development [7][8]. - Jinbo Biological's need for strategic investors is highlighted by its relatively small size and the increasing competition in the medical aesthetics industry [10][13].

Market Overview - The Hong Kong stock market experienced a high opening but closed lower, with the Hang Seng Index down 0.17% to 24,284.15 points and a total trading volume of HKD 275.115 billion [1] - The Hang Seng Index rose 3.2% over the week, while the Hang Seng China Enterprises Index and the Hang Seng Tech Index increased by 2.76% and 4.06%, respectively [1] Blue-Chip Stocks Performance - Xiaomi Group-W (01810) reached a new high, closing up 3.6% at HKD 58.95, contributing 58.62 points to the Hang Seng Index, following the launch of its first SUV, the Xiaomi YU7, which saw significant pre-order success [2][7] - Other notable blue-chip movements included Alibaba Health (00241) up 6.35%, Zijin Mining (02899) up 4.17%, while China Life (02628) and China Resources Land (01109) saw declines of 2.97% and 2.55%, respectively [2] Sector Highlights - Large tech stocks showed mixed results, with Xiaomi's YU7 orders boosting its stock, while Alibaba saw a slight decline [3] - The non-ferrous metals sector continued to rise, with Jiangxi Copper (00358) up 7.71% and Tianqi Lithium (09696) up 6.78%, driven by rising copper prices amid a squeeze in the London Metal Exchange [3] - The internet healthcare sector performed well, with Ping An Good Doctor rising over 8% and Alibaba Health up over 6% [3] AMC Sector Activity - The AMC sector saw significant gains, with China Cinda (01359) up 7.03% and CITIC Financial Assets (02799) up 2.38%, following announcements of asset management plans [4] - Analysts noted that long-term funds are increasingly seeking high-dividend assets, which may stimulate further activity in the banking sector [4] Notable Stock Movements - Saturday's Fortune (06168) surged 33.83% to HKD 40.15, driven by strong demand in the gold market and positive sentiment in the Hong Kong stock market [8] - Juzi Bio (02367) rebounded 5.75% to HKD 54.25, following announcements of share buybacks by its controlling shareholder [9] - Huaxing Capital Holdings (01911) rose 4.67% to HKD 4.48, after announcing plans to enter the Web3.0 and cryptocurrency sectors with a budget of USD 100 million [10] Weak Performers - Hong Kong Travel (00308) fell 25.63% to HKD 1.48, as the company undergoes strategic reviews without any confirmed decisions [11] - Rongchang Bio (09995) dropped 6.17% to HKD 55.55, attributed to market disappointment over its recent business development transaction [12]

Market Performance - The Hang Seng Healthcare Index (HSHCI) decreased by 1.16% as of June 27, 2025, with mixed performance among constituent stocks [3] - Ping An Good Doctor (01833) led the gains with an increase of 11.14%, while BeiGene (06160) experienced the largest decline at 8.75% [3][7] - The Hang Seng Healthcare ETF (513060) fell by 0.36%, with a latest price of 0.56 yuan and a turnover rate of 16.93% [3] Liquidity and Trading Activity - The Hang Seng Healthcare ETF saw a significant increase in scale, growing by 2.13 million yuan over the past week, ranking first among comparable funds [4] - The ETF recorded a net financing amount of 1.8212 million yuan this month, with a current financing balance of 319 million yuan [4] ETF Performance Metrics - The Hang Seng Healthcare ETF's net value increased by 15.70% over the past two years, with a maximum monthly return of 28.34% since inception [4] - The ETF's Sharpe ratio for the past year was 1.66, indicating strong risk-adjusted returns [4] - The ETF's management fee is 0.50%, and the custody fee is 0.15% [4] Valuation Insights - The current price-to-earnings ratio (PE-TTM) of the Hang Seng Healthcare Index is 27.07, which is below 91.38% of the historical data over the past three years, indicating a low valuation [5] - The top ten weighted stocks in the Hang Seng Healthcare Index account for 58.28% of the index, with notable companies including Innovent Biologics (01801) and BeiGene (06160) [5] Sector Outlook - Recent government encouragement for innovation has led to active performance in the innovative drug industry chain, despite ongoing pressures from medical insurance cost control [3] - Analysts suggest focusing on high-growth areas such as pharmaceutical outsourcing services and companies in the ophthalmology and dental sectors that are expected to improve profitability [3]

Core Viewpoint - Juzi Holding, the controlling shareholder of Juzi Bio, has shown confidence in the company's future by purchasing additional shares, indicating a positive outlook on the company's performance and potential growth [1] Summary by Relevant Sections - **Share Purchase Details** - Juzi Holding has acquired 1,056,600 shares of Juzi Bio since the announcement of the buyback plan on June 9, 2025, with a total investment of approximately 53.5 million HKD [1] - **Ownership Structure** - Following the share purchase, Juzi Holding now holds a total of 582 million shares, representing 54.36% of the company's total issued shares [1] - **Future Plans** - Juzi Holding may consider further increasing its stake depending on market conditions and regulatory requirements [1]

Core Viewpoint - The decline in newborn numbers from 17.86 million in 2016 to approximately 9 million in 2024 poses a significant challenge for the maternal and infant industry, leading to growth limitations for key players like Kidswant [1] Company Performance - Kidswant's performance has been under pressure since its 2021 IPO, with both revenue and net profit declining in 2022, and revenue growth without profit increase in 2023. A net profit of 181 million yuan was achieved in 2024, marking a year-on-year increase of 72.44%, largely due to the acquisition of Leyou International, which contributed 105 million yuan to net profit [1] - The company initiated a "three expansion strategy" in 2023, focusing on expanding product categories, market segments, and business formats to counteract growth stagnation [1] Strategic Acquisition - The acquisition of Siyi Industrial is a key move for Kidswant, as it aims to penetrate the hair care market. Siyi, established in 2014, operates 2,503 stores and has over 2 million members, showcasing strong financial performance with 2024 revenue of 723 million yuan and a net profit of 183 million yuan, reflecting a net profit margin of 25.3% [1] - The acquisition is designed to leverage overlapping customer bases, with 78% of Kidswant's 94 million members being mothers aged 25-45, aligning well with Siyi's target demographic [2] Financial Engineering - Kidswant's acquisition strategy involves holding 65% of Siyi and bringing in partners like Juzhi Biotechnology and the founders to share ownership, which helps bind industry resources while alleviating financial pressure. The initial funding of 660 million yuan includes 429 million yuan from Kidswant's raised funds, with the remaining 990 million yuan financed through loans, resulting in a leverage ratio of 1:2.85 [3] - The estimated valuation based on 2024 net profit suggests a price-to-earnings ratio of 9, which is below the average for the consumer sector and significantly lower than the assessed value [3] Market Concerns - Following the announcement of the acquisition, Kidswant's stock price dropped by 6.33%, raising concerns about the high assessment increase rate of 583.35% without performance guarantees. The company attributes this to intense bidding and the original shareholders exiting management [3] - The integration challenges are significant, as 93% of Siyi's stores are franchises, complicating standardization and management for Kidswant [3] Industry Outlook - The acquisition reflects Kidswant's proactive strategy to navigate the industry's downturn, with the success of this venture hinging on the effective implementation of synergies. The personal care market is projected to reach 81.25 billion yuan by 2028, with a compound annual growth rate of 7.3%, indicating a dissolving boundary between maternal and personal care sectors [4]

Core Viewpoint - The Hong Kong stock market experienced a decline in major indices, with the Hang Seng Index and the Hang Seng China Enterprises Index falling by 0.48% and 0.51% respectively, ending a four-day rally, while the Hang Seng Tech Index remained flat. The decline was particularly pronounced in innovative drug stocks and coal stocks, with Rongchang Biopharmaceuticals dropping nearly 17% [1]. Group 1: Market Performance - The Hang Seng Medical ETF (513060) saw a nearly 3% drop during trading, with a transaction volume exceeding 1.2 billion and a turnover rate over 15%, indicating strong buying interest despite the decline [1]. - Most component stocks within the ETF experienced declines, with notable drops including Yidu Tech (over 12%), and several others like Medlive Technology, Green Leaf Pharmaceutical, and Innovent Biologics falling over 5% [1]. Group 2: Rongchang Biopharmaceuticals - Rongchang Biopharmaceuticals entered a significant overseas licensing agreement for Taitasip with Vor Bio, with a headline amount of $1.25 billion upfront plus up to $4.1 billion in milestone payments. However, the core terms fell short of market expectations [1][2]. - The upfront payment structure was less favorable than anticipated, with only $45 million in cash and the remainder in warrants, leading to lower actual cash inflow compared to previous licensing deals [2]. - The milestone payments of up to $4.1 billion are contingent on multiple conditions, including clinical and regulatory approvals, with high uncertainty regarding the development of Taitasip for U.S. SLE indications [2]. Group 3: Risk Factors - The unique risk structure of innovative drug companies makes their stock prices sensitive to single events, such as critical data releases for ongoing clinical trials [3]. - Rongchang Biopharmaceuticals reported a loss of nearly 1.47 billion in 2024, with Q1 2025 operating cash flow still negative at 188 million [4]. - The competitive landscape for Taitasip faces challenges from FcRn inhibitors and other therapies, raising questions about the sustainability of clinical advantages [4]. Group 4: Industry Insights - The volatility observed in individual stocks is not isolated, as similar fluctuations have been noted in the innovative drug sector, highlighting the sensitivity and fragility of stock prices to news [2]. - The Hang Seng Medical Healthcare Index, which includes 68 companies, limits the impact of individual stock volatility on the overall index performance [4]. - The Hang Seng Medical ETF (513060) serves as a diversified tool to mitigate individual stock event risks, with a significant concentration in the top ten component stocks [4][5]. - The index is currently at a historical low valuation, with a PE-TTM of 27.49, indicating a potential opportunity for investors to diversify through the ETF while sharing in the overall industry growth [5].

今天分享的是：2025美丽消费专题：从海外三大美妆集团中报看大众国货β机会 报告共计：27页 国际美妆巨头中报透露行业变局：国货品牌迎来大众市场突围关键期 2024年已过半，欧莱雅、雅诗兰黛、资生堂这三大国际美妆集团的中期业绩报告，为全球美妆市场的走向提供了重要参考。从 这些报告中可以看出，国际美妆行业的格局正在发生深刻变化，而中国大众国货品牌也迎来了难得的发展机遇。 国际巨头业绩分化，战略重心各有调整 欧莱雅在2024年上半年的表现可圈可点，实现了221.21亿欧元的销售额，同比增长7.3%。值得关注的是，其大众业务部门的增 速持续高于高端业务，占比重新回到第一，达到37%-38%。像巴黎欧莱雅这样的核心品牌表现亮眼，增速高达13%。在区域布 局上，欧莱雅积极拓展新兴市场，目前新兴市场的销售规模已经与中国市场接近，均占其销售收入的17%左右。对于中国市 场，欧莱雅表示不会参与过度的价格竞争，而是更注重通过创新产品来提升市场份额。 雅诗兰黛的2024财年（2023年7月至2024年6月）则面临一定挑战，营收为156.1亿美元，同比下降1.9%。主要原因是中国大陆地 区高端美妆消费持续疲软，以及亚太区旅游零售市 ...